Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

Pandemic influenza remains a significant global health threat, as signalled by the circulation and cross-species transmission of avian influenza A(H5N1) viruses from the clade 2.3.4.4b, including ...

Turnover rose seven per cent at constant exchange rates to £31.4bn or eight per cent, excluding Covid pandemic-related sales. GSK announced a 16p per share dividend for the fourth quarter ...

AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.

The biotech is partnered with GSK to provide a monoclonal antibody (mAb) as a treatment for COVID-19. A spokesperson for the biotech told pharmaphorum, “The COVID-19 pandemic highlighted the ...

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could ...

The Public Health Agency of Canada said Wednesday it's purchased 500,000 doses of a human vaccine to protect against avian ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on ...

Much like every other brand in 2020, GlaxoSmithKline (GSK) – the consumer healthcare company – had its business completely upended by the COVID-19 pandemic, and was forced to reshape its marketing ...